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SUMMARY. Suppose that the random effect distribution of the parameter of interest in meta
analysis is completely unspecified. We propose a simple nonparametric interval estimation
procedure for making inferences about the percentiles, for example, the median, of this
distribution. Regardless of the number of studies involved, the new proposal is theoretically
valid provided that the individual study sample sizes are large. Based on an extensive
numerical study, we find that the procedure performs well even with moderate study sample
sizes. The new method can be implemented with study-level summary statistics. The
proposal is illustrated with the data from a recent meta analysis to investigate the potential
treatment-related toxicity from erythropiesis-stimulating agents (ESAs) for treating cancer
patients with anemia (Bennett et al., 2008).
Keywords: Bivariate beta; Conditional permutation test; Erythropiesis-stimulating agents;
Logit-normal, Two-level hierarchical model.
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1. Introduction
Meta analysis techniques have been utilized frequently to make inferences about the distri-
bution of an unobservable random parameter. Under the fixed effect modeling setting, this
distribution has a single unknown mass point. The standard estimation procedure for such
a fixed parameter value utilizes a weighted average of study-specific point estimates. For
analyzing multiple 2 × 2 tables, the most commonly used procedures are Mantel-Haenszel
(Mantel and Haenszel, 1959) and Peto methods (Yusuf et al., 1985). It is important to note
that these methods are valid asymptotically, that is, when the number of studies and each
individual study sample size are large. Moreover, for the case that the event rate is small,
these standard methods may not perform well. Recently, Tian et al. (2008) proposed a
general exact interval estimation procedure under the fixed effect model, which combines
study-specific exact confidence intervals instead of point estimates across the studies.
Often the fixed effect modeling assumption may not be realistic. The study-specific pa-
rameter values may vary markedly across sub-groups of the population. Under the random
effect model, the procedure for estimating the mean of the random effect distribution pro-
posed by DerSimonian and Laird (DL) (1986) is commonly used in practice. Their method
utilizes a linear combination of study-specific estimates of the parameter with the weights
depending on the within- and among-study variance estimates. This procedure is simple to
implement and does not require patient-level data. The validity of the procedure, however,
heavily depends on the individual sample sizes and the number of studies (Brockwell and
Gordon, 2001; Bohning et al., 2002; Sidik and Jonkman, 2007; Viechtbauer, 2007). Recently,
various novel alternatives or modifications to the DL method have been proposed, for ex-
ample, by Hardy and Thompson (1996), Biggerstaff and Tweedie (1997), Hartung (1999),
Hartung and Knapp (2001a, 2001b) and DerSimonian and Kacker (2007). Their validity,
however, is not clear when the number of studies is not large or the parametric assumption
for the random effect is violated. An excellent review on meta analysis with the random
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effect model is given by Sutton and Higgins (2008).
In this article, we propose a simple interval estimation procedure for the percentiles of the
random effect distribution based on study-level data without assuming a parametric form
of the distribution. When the random effect distribution is not symmetric, its median may
be a better measure as the center than the mean for which the DL and its generalizations
try to estimate. Moreover, our inference procedure may provide information beyond the
center of the distribution of the random parameter if the number of studies is not too small.
Regardless of the number of studies involved in the analysis, the new proposal is theoretically
valid when the sample sizes of individual studies are large. An extensive numerical study
was conducted to examine the performance of the new proposal under various practical
settings. We find that our interval estimation procedure for percentiles of the random effect
distribution has correct coverage level. Moreover, when the empirical level of the DL method
is close to its nominal counterpart, our corresponding interval estimate has comparable
length. We illustrate the method with the data from a recent meta analysis for evaluating
potential treatment-related toxicity of erythropiesis-stimulating agents (ESAs) for treating
cancer patients with anemia (Bennett et al., 2008). For some cases, our results are markedly
different from those reported in Bennett et al.
It is important to note that when patient level data are available, various novel procedures
have been studied for the mixed effects regression models for continuous, discrete or censored
event time observations (Laird and Ware, 1982; Hougaard, 1995; Hogan and Laird, 1997;
Henderson et al, 2000; Lam, Lee and Leung, 2002; Nelder, Lee and Pawitan, 2006; Cai,
Cheng and Wei, 2002; Zeng and Lin, 2007; Zeng, Lin and Lin, 2008). To the best of our
knowledge, all the existing asymptotical procedures for mixed effects models assume that
3
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the number of studies is large.
2. Interval Estimates for Percentiles of the Random Effect Distribution
Consider a typical two-level hierarchical model. Let Π′ = (Θ,Λ′) be a row vector of random
parameters, where Θ is a univariate parameter of interest and Λ is a finite- or infinite-
dimensional vector of nuisance parameters. Let G(·) be the continuous, completely un-
specified distribution function of Θ. Given an unobservable realization Π, a data set X is
generated. Let {Πk, Xk}, k = 1, · · · , K, be K independent copies of {Π, X}. The problem is
how to make inferences, for instance, about the median µ0 of G(·) with {Xk, k = 1, · · · , K}.
As an example, consider the case with K 2 × 2 tables and let Θk be the log-risk-ratio or
risk difference for the kth table. Here, the nuisance parameter Λk consists of the underlying
event rate for the “control” group and the sample size for the kth study.
If we can observe {Θk, k = 1, · · · , K}, a simple nonparametric estimator for µ0 is the
sample median. Exact confidence intervals for µ0 can be obtained by inverting a sign test
statistic
T (µ) =
K∑
k=1
{I(Θk < µ)− 1/2}, (1)
for testing the null hypothesis that the median µ0 is µ, where I(·) is the indicator function.
The null distribution of T (µ0) +K/2 is a binomial with size K and “success” probability of
1/2.
Suppose that given Πk, Θˆk is a consistent estimator for Θk based on the data Xk. Also,
suppose that the distribution of Θˆk is approximately normal with mean Θk and variance
σˆ2k, k = 1, · · · , K. To obtain confidence intervals for µ0 without observing Θk directly, one
may replace Θk with Θˆk in the test statistic T (·). Let the corresponding test statistic be
denoted by T˜ (·). When the sample size nk for the kth study, k = 1, · · · , K, is large, the
unconditional null distribution of T˜ (µ0) +K/2 is approximately binomial with size K and
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success rate of 0.5. Unfortunately the variable I(Θˆk < µ) may not be a good surrogate
for I(Θk < µ) especially when the variance σˆ
2
k of Θˆk is large with respect to the distance
between the unobserved realized Θk and µ. For this case, the chance of observing the event,
{Θˆk < µ} can be very close to 1/2 (like tossing a fair coin), and the noise generated from such
an unstable variable {I(Θˆk < µ) − 1/2} may well out-weight its added value to the power
of the test based on T˜ (µ). An alternative approach is to replace the indicator I(Θˆk < µ)
with a measure of likelihood for the event, Θk < µ, for example, the observed coverage level
of the interval (−∞, µ) for the realized Θk. Under the present setting, this coverage level
is approximately Φ((µ − Θˆk)/σˆk), where Φ(·) is the distribution function of the standard
normal. The resulting test statistic is
Tˆ (µ) =
K∑
k=1
{Φ((µ− Θˆk)/σˆk)− 1/2}. (2)
Note that if for the kth study, the data Xk are quite informative for the event, Θk < µ, that
is, the coverage level of (−∞, µ) for Θk is close to either one or zero, this study carries heavy
weight in the statistic Tˆ (µ).
In the Appendix we show that in probability, for any given µ,
Φ((µ− Θˆk)/σˆk)− I(Θk < µ)→ 0, as nk →∞. (3)
Therefore, for fixed K, for large nk, k = 1, · · · , K, the distribution of Tˆ (µ) can be approx-
imated by that of T (µ). This approximation, however, is rather discrete and for moderate
sample sizes, the resulting confidence intervals for µ0 do not have adequate coverage levels
based on our extensive numerical study discussed in Section 4. Moreover, this limiting null
distribution is generated by weighting all K studies equally. Now, from (3), asymptoti-
cally, Φ((µ − Θˆk)/σˆk) is symmetric around 1/2. This motivates us to consider the following
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procedure to generate an approximation to the null distribution of Tˆ (µ). First, let
T ∗(µ) =
K∑
k=1
|Φ((µ− Θˆk)/σˆk)− 1/2|(2∆k − 1), (4)
where {∆k, k = 1, · · · , K} is a random sample, independent of the data, from a Bernoulli
with success probability of 1/2. Then, conditional on the data, we repeatedly generate M
realizations of {∆k} to obtain the null distribution. A relatively large or small observed
value of Tˆ (µ) compared with this generated reference distribution suggests a rejection of the
hypothesized median value µ of G(·). In the Appendix, we justify the asymptotic validity of
the test based on (2) and (4). Confidence intervals for µ0 can be obtained by inverting this
test. In contrast to the existing methods in the literature, the new proposal is valid with any
fixedK, the number of studies involved in the analysis. In the Section 4, we show empirically
that the resulting interval estimation procedure performs well even when the sample sizes
{nk} are not large.
When the number of studies is not small, the above proposal can be easily generalized to
the case for making inferences about certain percentiles of the distribution G(·). Specifically,
let us hypothesize that the 100pth percentile µ0 is µ. The test statistic is then
Tˆp(µ) =
K∑
k=1
{Φ((µ − Θˆk)/σˆk)− 1/2}. (5)
Note that we use 1/2 in the above {·} instead of p. The rationale is that for the kth
study, the term Φ(·) is a measure of likelihood that the unknown fixed Θk is less than µ. If
this likelihood is around 1/2, we give this study very little weight in (5). Unconditionally,
Tˆp(µ0) + K/2 is asymptotically binomial with mean of Kp and size of K. Again, like the
case with median, this limiting distribution puts equal weights for all individual studies and
therefore may not be a good approximation to the null distribution of (5) for finite sample
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sizes {nk, k = 1, · · · , K}. Instead, conditional on the data, an approximation to the null
distribution can be generated via the random quantity
Tˆp(µ) =
K∑
k=1
|Φ((µ− Θˆk)/σˆk)− 1/2|(2k − 1), (6)
where {k, k = 1, · · · , K} is a random sample from a Bernoulli with success probability
of p. Confidence intervals for the 100pth percentile can then be obtained by inverting this
conditional permutation test accordingly. For inference about the pth percentile, we let the
counterpart of T˜ (·) be denoted by T˜p(·)
Note that the likelihood measure of the event Θk < µ does not have to be based on
the large sample normal approximation to the distribution of Θˆk. For example, in dealing
with multiple 2× 2 tables with rare events, often there are studies without any events. For
this case, the variance of Θˆk, say, the risk difference estimator, cannot be estimated without
using continuity correction. On the other hand, for each study, one may construct the exact
confidence intervals for Θ and use the exact level for the interval (−∞, µ) to replace Φ(·)
in (2), (4), (5) and (6) for testing the hypothesized percentile value. Lastly, to avoid the
conservativeness of the test, for example, based on T˜ (·), due to its discrete null distribution,
we used the standard mid p-value method to implement the test procedure.
3. Examples
We use two examples to illustrate the new proposal. The first one is with survival time
observations and the second example deals with multiple 2×2 tables. In a recent meta anal-
ysis, Bennett et al. (2008) examined whether the erythropoiesis-stimulating agents (ESAs)
for treating cancer-related anemia would increase the patient’s risk of mortality with the
study-level data from 51 phase III comparative trials (ESA vs. placebo or standard of care).
In Table 1 (copied from Figure 2 of Bennett et al.), we list their two-sample hazard ratio
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point and 95% interval estimates. Here, K = 51, and for the kth study, Θk is the log-hazard
ratio and Θˆk is its estimate. Since the patient-level data are not available, we approximate
the standard error estimate of Θˆk by one fourth of the reported length of the 95% confi-
dence interval (converted to the log-scale), k = 1, · · · , K. The 95% confidence interval for
the median of the distribution of the random hazard ratio (exp(Θ)) are (0.94, 1.21) based on
the test statistic Tˆ (·) and (4). The corresponding interval based on the indicator functions
{I(Θˆk < µ)} via T˜ (µ) is (0.90, 1.26), which is wider than the above interval. Note that the
95% confidence interval for the mean of the random effects distribution reported in Bennett
et al. (2008) using DL method is (1.01, 1.20), which excludes the null value one, indicating
that mortality for ESAs is significantly higher than that for the control group. On the other
hand, our results are not statistically significant.
The 95% intervals for the 25th and 75th percentiles based on (5) and (6) are (0.70, 0.99)
and (1.18, 1.48), respectively. The counterparts based on T˜p(·) are (0.49, 0.93) and (1.25, 1.72).
Again, the intervals based on Tˆp(·) are shorter than those with T˜p(·).
The cancer-related anemia case was also evaluated by Bennett et al. (2008) with six
studies (see the top portion of Table 1). The 95% confidence intervals based on Tˆ (·), T˜ (·)
and DL method are (0.55, 1.94), (0.50, 3.96) and (1.00, 1.67), respectively. Note that the DL
interval is quite different from ours. The null value well sits in our interval, but not in theirs.
In the next section, we show that the empirical coverage levels of the DL method can be
substantially lower than their nominal counterparts even when the number of studies is not
that small (say, K = 40).
Bennett et al. (2008) also investigated whether ESAs would increase the risk of venous
thromboembolism event (VTE) from 38 comparative phase III trials (Table 2, copied from
Figure 3 of Bennett et al.). Note that there are 41 studies listed in Table 2. Since three
studies do not have any VTE events, as Bennett et al. did, our analysis is based on the study-
level data from 38 trials. Here, we let Θ be the log-relative-risk (not the relative-risk). Again,
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we use their 38 sets of point and 95% interval estimates for the relative risk to construct 95%
confidence intervals for the median of the random relative risk based on Tˆ (·) and T˜ (·). These
intervals are (1.54, 2.53) and (1.52, 3.00) respectively. The corresponding interval based on
the DL method is (1.31, 1.87). The 95% intervals for the 25th and 75th percentiles for the
relative risk distribution based on Tˆp(·) in (5) are (1.05, 1.72) and (2.09, 3.97), respectively.
The counterparts based on the indicators T˜p(·) are (0.75, 1.84) and (2.80, 4.93).
4. Numerical Study to Evaluate Performance of the New Proposal
We conducted an extensive numerical study to examine the performance of the proposed
interval estimation procedure for the percentiles of the random effect model under various
practical settings. For comparisons, we included the DL interval estimation method and the
one based on T˜ (·). In our study we considered cases with binary or continuous responses,
various symmetric or asymmetric random effect distributions, and a wide range of study
sample sizes and number of studies. Based on the results of our numerical investigation, we
find that the new proposal performs well with respect to the confidence interval coverage
level and length. The DL method tends to be liberal, that is, the empirical coverage levels
can be markedly lower than their nominal counterparts. The procedure based on the test
statistic T˜ (·) produces confidence intervals whose average lengths are uniformly wider than
those with our method. When we deal with percentiles other than median, the method based
on T˜p(·) may have the under-coverage problem.
More specifically, in one part of our numerical study, we considered meta analysis for
multiple 2× 2 tables under the settings similar to that presented in Table 2. In Table 2 for
the VTE rate comparisons, there are 41 studies listed and the raw data are available for 40
studies. We let Θk = log(P1k/P0k) be the log-relative risk for the kth study, where P1k and
P0k are the underlying event rates for the ESA and control groups, respectively. We then
assumed that the random vector (logit(P0k), logit(P1k))
′ was a random sample with size K
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from a bivariate normal, whose mean η and variance-covariance matrix Σ were estimated
by their sample counterparts via the observed rates in Table 2 (note that we used the
conventional 0.5 continuity correction for studies with zero cells). The resulting sample
means and variance-covariance matrix are (−3.56,−2.86)′ and


0.90 0.62
0.62 1.10

 , respectively.
The density of Θ is given in Figure 1 (panel (a)), which appears to be quite symmetric.
For each realization {(P0k, P1k)
′, k = 1, · · · , K}, we generated the corresponding set of 2× 2
tables. We then used three aforementioned methods with this realized data set to construct
three 95% confidence intervals for the median of the log-relative risk random parameter Θ.
For each realized dataset, we excluded studies with 0-0 cells (that is, no events occurred
in either group), and used the 0.5 continuity correction for studies with one zero cell. The
average empirical coverage levels and the median interval lengths were obtained with 2000
realized data sets. Under the same setting, we repeated this process with different K, the
number of studies in our simulated meta analysis. For each K, the sample sizes were chosen
from the first K studies listed in Table 2. The results are summarized in Table 3 (left half).
The average coverage levels for our method range from 0.94 to 0.95. On the other hand,
the average empirical coverage level for the DL method can be as low as 0.86. The median
lengths of our method are uniformly shorter than those of the procedure using T˜ (·). In Table
4 (left half), we report the results for the 25th and 75th percentiles. Again our proposal
behaves well, but the one with T˜p(·) may not have correct coverage level.
We also considered cases with rather asymmetric random effect distribution. For example,
we consider a bivariate beta distribution for {(P0k, P1k)
′, k = 1, · · · , 40} via three independent
gamma random variables which have a common unit scale parameter and shape parameters
of 2, 8, and 10, respectively (Olkin and Liu, 2003). The density function of the random
parameter Θ, the log-relative risk, is given in Figure 1 (panel (b)). Under the same setting
as the previous simulation, the results are reported in the right half portions of Tables 3
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and 4. Again, the new procedure performs well. The DL method still has coverage problem.
Note that the DL method provides confidence interval estimates for the mean of G(·), not
the median. We then investigated the coverage properties of the DL method for the mean
and found that the empirical coverage of the DL intervals were also lower than the nominal
level 95% in this setting. For example, when K = 40, the coverage for the mean is only 64%.
Although our method is developed assuming that the random effect distribution is contin-
uous, we also considered cases with fixed effect models in our numerical study. For example,
we let (P0k, P1k) = (0.1, 0.2), k = 1, · · · , K. The results are summarized in Table 5. For this
case, the DL method has correct coverage level for most scenarios under which our interval
estimation procedure is comparable with the DL method with respect to the interval length.
We also studied the performance of our method for Θk = P1k − P0k, the risk difference for
the kth study. The results were very similar to those for the relative risk.
5. Remarks
In this article, we present a simple nonparametric interval estimation procedure for per-
centiles of the random effect model. In contrast to existing methods, the new proposal does
not require that the number of studies is large. Moreover, if the random effect distribution is
symmetric and the exact distribution of Θˆk, k = 1, · · · , K, is symmetric around the unknown
fixed realized Θk, it is easy to show that the resulting interval estimators based on Tˆ (·) for
the median (or mean) are valid regardless the sizes of the individual studies or the number
of studies. For instance, under the usual two-sample location shift model with continuous
response variable, let Θ be the location shift parameter of interest. Then, the two-sample
rank estimator Θˆk is symmetric around Θk under rather mild conditions (Lehmann, 1975 ,
p. 86). If the unspecified random effect distribution is symmetric around µ0, one can use
our procedure to obtain exact confidence intervals for µ0.
Note that if the fixed effect model is approximately correct, the existing interval proce-
11
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dures for the common parameter value µ0 may be more efficient than those developed under
the random effect model. The standard heterogeneity tests genearlly do not have power to
detect inadequacy of the fixed effect modeling assumption. Therefore, in practice, sensitivity
analysis with both random and fixed effect models is highly recommended.
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APPENDIX
Justification for the validity of the conditional permutation test Tˆ (·) based on
the approximation generated by T ∗(·)
Let Dk = Φ((µ − Θˆk)/σˆk) − I(Θk < µ). We show that Dk goes to 0, in probability, as
nk → ∞. Here, the probability is generated by the random element (Xk,Πk). For any fixed
positive constant c, first we show that pr(|Dk| ≥ c | Πk)→ 0 for any given Πk with Θk 6= µ.
To this end, consider two cases. First, if Θk < µ, then conditional on Πk,
|Dk| = |Φ((µ − Θˆk)/σˆk)− 1| = 1− Φ((µ −Θk)/σˆk + (Θk − Θˆk)/σˆk).
As nk → ∞, (µ − Θk)/σˆk → ∞ in probability, and (Θk − Θˆk)/σˆk → N(0, 1) in distribu-
tion. Therefore, for any c > 0, we can find N such that when nk > N , pr((µ − Θk)/σˆk +
(Θk − Θˆk)/σˆk ≤ Φ
−1(1 − c)) < c, which is equivalent to pr(Φ((µ − Θˆk)/σˆk) < 1 − c) =
pr(|Dk| ≥ c) < c. Therefore, pr(|Dk| ≥ c | Πk) → 0. Similarly if Θk > µ, we can show that
pr(|Dk| ≥ c | Πk) → 0 as nk → ∞. Therefore, pr(|Dk| ≥ C | Πk) → 0 for any Πk such that
Θk 6= µ. These, coupled with the fact that G(·) is continuous, implies that pr(|Dk| ≥ c) =
EΠk {pr(|Dk| ≥ c | Πk)} → 0 for any c by the dominate convergence theorem. Therefore,
Dk → 0 in probability as nk →∞. It follows that |Tˆ (µ) −
∑K
k=1(I(Θk < µ) − 1/2)| → 0, in
probability, as min{n1, · · · , nK} → ∞. Similarly, since
∣∣∣∣ |Φ((µ− Θˆk)/σˆk)− 1/2|(2∆k − 1)− |I(Θk < µ)− 1/2|(2∆k − 1)
∣∣∣∣≤ |Dk|,
one can show that T ∗(µ) −
∑K
k=1 |I(Θk < µ) − 0.5|(2∆k − 1) → 0, in probability as
min{n1, · · · , nK} → ∞, where ∆k is a random sample from a Bernoulli with a success
16
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probability of 1/2. Therefore, for any t and positive c,
pr{(Xk,Πk)k=1,···,K}
(∣∣∣∣ pr(T ∗(µ) ≤ t|(Xk,Πk)k=1,···,K)−
pr(0.5
K∑
k=1
(2∆k − 1) ≤ t
∣∣∣∣≥ c
)
≤ c,
when min{n1, · · · , nK} is large. This, coupled with the fact that
∑K
k=1(I(Θk < µ) − 1/2) ∼
0.5
∑K
k=1(2∆k − 1) under the null hypothesis, implies that one can approximate the null
distribution of Tˆ (µ) by the distribution of T ∗(µ) conditional on the observed data.
17
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Table 1: Study-level Summary Statistics for Mortality for Cancer Studies with ESAs vs
Control from Bennett et al (2008)
Study Two Sample Hazard Ratio
Point Estimate 95% Confidence Interval
Anemia of Cancer Mystakidou et al,22 2005 0.50 (0.05-4.99)
Gordon et al,17 2006 0.67 (0.23-2.00)
Abels,28 1993 0.89 (0.41-1.93)
Charu et al,15 2007 1.38 (0.44-4.33)
Glaspy et al,19 2007 1.43 (1.06-1.92)
Smith et al,52 2003 3.96 (0.29-54.12)
Treatment-Related Anemia Throuvalas et al,55 2000 0.13 (0-332.66)
Dunphy et al, 35 1999 0.14 (0-6.88)
Vadhan-Raj et al, 56 2004 0.15 (0-415.90)
Dammacco et al, 33 2001 0.32 (0.11-0.95)
Del Mastro et al, 34 1997 0.36 (0.05-2.56)
Cazzola et al, 31 1995 0.37 (0.06-2.27)
P-174,11 2004 0.41 (0.03-5.76)
Thatcher et al, 54 1999 0.49 (0.03-8.71)
Kotasek et al, 39 2003 0.55 (0.11-2.71)
Oberhoff et al, 44 1998 0.61 (0.24-1.55)
Blohmer et al, 24 2003 (AGO/NOGG) 0.67 (0.34-1.33)
Henry and Abels, 38 1994 0.75 (0.28-2.01)
Vansteenkiste et al,2 2002 0.78 (0.60-1.01)
Littlewood et al, 41 2001 0.81 (0.62-1.06)
Taylor et al, 21 2005 (DA 232) 0.85 (0.45-1.60)
EPO-CAN-17,12 2007 0.88 (0.49-1.59)
Amgen DA 145, 13 2007 0.93 (0.82-1.05)
Razzouk et al, 49 2004 0.98 (0.14-6.90)
Savonije et al, 51 2004 0.98 (0.36-2.67)
ten Bokkel Huinink et al, 53 1998 1.01 (0.19-5.31)
Osterborg et al, 46 1996 1.02 (0.51-2.04)
Coiffier et al, 32 2001 1.02 (0.38-2.73)
Debus et al, 16 2007(EPO-GER-22) 1.02 (0.60-1.74)
Osterborg et al, 47 2005 1.04 (0.80-1.35)
EPO-GBR-7, 12 2007 1.07 (0.73-1.57)
Case et al, 30 1993 1.08 (0.44-2.66)
Witzig et al, 57 2005 1.09 (0.83-1.43)
Moebus et al, 18 2007 1.14 (0.77-1.69)
Strauss et al, 23 2007 1.16 (0.69-1.95)
Thomas et al, 36 2007 (GOG-191) 1.25 (0.65-2.41)
Thatcher et al, 54 1999 1.26 (0.24-6.60)
Overgaard et al, 14 2007 (DAHANCA 10) 1.28 (0.97-1.69)
Hedenus et al, 37 2003 1.36 (0.98-1.89)
Leyland-Jones et al, 40 2005 (INT-76) 1.37 (1.07-1.75)
Henke et al, 5 2003 1.39 (1.05-1.84)
Machtay et al, 42 2007 (RTOG 99-03) 1.41 (0.80-2.49)
PREPARE, 48 2007 1.50 (0.96-2.34)
Grote et al, 43 2005 (N93-004) 1.53 (0.65-3.61)
INT-3, 11 2004 1.56 (0.42-5.79)
INT-1, 11 2004 1.58 (0.32-7.82)
Rose et al, 50 1994 1.68 (0.66-4.29)
Bamias et al, 29 2003 1.80 (0.53-6.12)
Wright et al, 58 2007 (EPO-CAN-20) 1.84 (1.01-3.35)
EPO-CAN-15, 11 2004 2.70 (1.17-6.23)
Wilinson et al, 20 2006 4.54 (0.40-51.20)
O’Shaughnessy et al, 45 2005 7.39 (0.15-366.10)
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Table 2: Event Rates and Study-Level Summary Statistics for VTE for Cancer Studies with
ESAs vs Control from Bennett et al. (2008)
No. of VETevents/No. of patients Relative Risk
Study ESA Control Point Estimate 95% CI
Bamias et al, 29 2003 0/72 1/72 0.33 (0.01-8.05)
Smith et al, 52 2003 1/64 1/22 0.34 (0.02-5.27)
Case et al, 30 1993 2/81 3/76 0.63 (0.11-3.64)
Henry and Abels, 38 1994 6/67 8/65 0.73 (0.27-1.98)
Wright et al, 58 2007 (EPO-CAN-20) 2/33 3/37 0.75 (0.13-4.20)
Grote et al, 43 2005 (N93-004) 24/109 26/115 0.97 (0.60-1.59)
EPO-CAN-17, 12 2007 19/175 14/175 1.36 (0.70-2.62)
Littlewood et al, 41 2001 14/251 5/124 1.38 (0.51-3.75)
Vansteenkiste et al, 2 2002 7/155 5/159 1.44 (0.47-4.43)
INT-1, 11 2004 3/164 1/80 1.46 (0.15-13.85)
Leyland-Jones et al, 40 2005 (INT-76) 36/448 25/456 1.47 (0.89-2.40)
Witzig et al, 57 2005 9/168 6/165 1.47 (0.54-4.05)
Osterborg et al, 46 1996 1/48 0/24 1.53 (0.06-36.23)
Amgen DA 145, 13 2007 66/298 43/298 1.53 (1.08-2.18)
Henke et al, 5 2003 10/180 6/171 1.58 (0.59-4.26)
ten Bokkel Huinink et al, 53 1998 2/45 0/17 1.96 (0.10-38.79)
Debus et al, 16 2007 (EPO-GER-22) 20/108 10/107 1.98 (0.97-4.03)
Charu et al, 15 2007 Not Available 2.36 (0.13-43.20)
Rose et al, 50 1994 9/142 2/79 2.50 (0.55-11.30)
Thatcher et al, 54 1999 2/44 0/22 2.56 (0.13-51.05)
Osterborg et al, 46 1996 2/47 0/25 2.71 (0.14-54.32)
Abels, 28 1993 1/65 0/59 2.73 (0.11-65.68)
Throuvalas et al, 55 2000 1/28 0/26 2.79 (0.12-65.66)
GOG-191, 11 2007 9/58 3/55 2.84 (0.81-9.96)
Razzouk et al, 49 2004 6/112 2/110 2.95 (0.61-14.28)
Welch et al, 61 1995 1/15 0/15 3.00 (0.13-74.41)
Osterborg et al, 47 2005 1/170 0/173 3.05 (0.13-74.41)
Gordon et al, 17 2006 4/162 0/56 3.15 (0.17-57.55)
ten Bokkel Huinink et al, 53 1998 4/42 0/16 3.56 (0.20-62.58)
Vadhan-Raj et al, 56 2004 7/29 2/31 3.74 (0.85-16.56)
INT-3, 11 2004 8/135 1/65 3.85 (0.49-30.15)
Wilkinson et al, 20 2006 12/173 1/59 4.09 (0.54-30.80)
Savonije et al, 51 2004 9/211 1/104 4.44 (0.57-34.55)
Machtay et al, 42 2007 (RTOG 99-03) 2/71 0/70 4.93 (0.24-100.89)
EPO-GBR-7, 12 2007 5/151 1/149 4.93 (0.58-41.73)
Dammacco et al, 33 2001 5/69 1/76 5.51 (0.66-45.98)
EPO-CAN-15, 11 2004 16/53 2/53 8.00 (1.93-33.09)
Rosenzweig et al, 60 2004 4/14 0/13 8.40 (0.50-142.27)
Cascinu et al, 59 1994 0/50 0/50
P-174, 11 2004 0/33 0/12
Thatcher et al, 54 1999 0/42 0/22
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Table 3: Empirical Coverage Levels (ECL) And Median Lengths (ML) For 0.95 Interval
Estimates For Median Based On DerSimonian-Laird (DL), Tˆ (·) and T˜ (·) With A Bivariate
Logit-Normal Or A Bivariate Beta Distribution For The Two Underlying Random Event
Rates
Bivariate Logit-Normal Bivariate Beta
Number of DL Tˆ (·) T˜ (·) DL Tˆ (·) T˜ (·)
Studies K ECL, ML ECL, ML ECL, ML ECL, ML ECL, ML ECL, ML
40 0.86, 0.62 0.94, 0.72 0.95, 0.90 0.87, 0.40 0.95, 0.52 0.96, 0.65
30 0.88, 0.71 0.94, 0.83 0.95, 1.03 0.88, 0.46 0.95, 0.61 0.96, 0.75
20 0.88, 0.85 0.94, 1.00 0.95, 1.23 0.90, 0.55 0.96, 0.75 0.96, 0.91
10 0.88, 1.18 0.95, 1.54 0.97, 2.15 0.91, 0.76 0.96, 1.10 0.98, 1.56
6 0.91, 1.57 0.95, 2.29 0.97, 2.89 0.88, 1.00 0.95, 1.58 0.97, 2.10
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Table 4: Empirical Coverage Levels (ECL) and Median Lengths (ML) for 0.95 Confidence Intervals For The 25th And
75th Percentiles Based On Tˆp(·) and T˜p(·) With A Bivariate Logit-Normal Or A Bivariate Beta Distribution For The
Two Underlying Random Event Rates
Bivariate Logit-Normal Bivariate Beta
p25 p75 p25 p75
Number of Tˆp(·) T˜p(·) Tˆp(·) T˜p(·) Tˆp(·) T˜p(·) Tˆp(·) T˜p(·)
Studies K ECL, ML ECL, ML ECL, ML ECL, ML ECL, ML ECL, ML ECL, ML ECL, ML
40 0.95, 0.86 0.86, 1.16 0.95, 0.81 0.92, 0.92 0.96, 0.48 0.93, 0.55 0.96, 0.73 0.92, 0.96
35 0.96, 0.91 0.88, 1.21 0.96, 0.86 0.90, 1.02 0.96, 0.52 0.95, 0.61 0.96, 0.78 0.93, 1.04
30 0.96, 1.00 0.90, 1.37 0.96, 0.94 0.91, 1.12 0.95, 0.56 0.94, 0.64 0.96, 0.85 0.93, 1.07
25 0.96, 1.12 0.90, 1.49 0.97, 1.06 0.92, 1.23 0.96, 0.62 0.93, 0.65 0.96, 0.94 0.92, 1.10
20 0.96, 1.24 0.92, 1.52 0.97, 1.16 0.92, 1.32 0.96, 0.72 0.95, 0.80 0.96, 1.37 0.95, 1.3721
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Table 5: Empirical Coverage Levels (ECL) And Median Lengths (ML) For 0.95 Interval
Estimates For Median Based On DerSimonian-Laird (DL), Tˆ (·) and T˜ (·) With A Fix Effect
Model (The Underlying Event Rates Are 0.1 and 0.2)
Number of DL Tˆ (·) T˜ (·)
Studies K ECL, ML ECL, ML ECL, ML
K = 40 0.92, 0.24 0.95, 0.27 0.96, 0.35
K = 30 0.94, 0.26 0.95, 0.30 0.96, 0.39
K = 20 0.95, 0.30 0.95, 0.35 0.97, 0.45
K = 10 0.97, 0.47 0.96, 0.57 0.98, 0.84
K = 6 0.96, 0.75 0.95, 1.03 0.97, 1.34
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Figure 1: The True Density Functions For The Random Log-Relative-Risk Parameter For
The Simulation Study
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